| Literature DB >> 17727703 |
Abstract
BACKGROUND: Most genetic disorders are linked to missense mutations as even minor changes in the size or properties of an amino acid can alter or prevent the function of the protein. Further, the effect of a mutation is also dependent on the sequence and structure context of the alteration.Entities:
Mesh:
Year: 2007 PMID: 17727703 PMCID: PMC1995201 DOI: 10.1186/1472-6807-7-56
Source DB: PubMed Journal: BMC Struct Biol ISSN: 1472-6807
Summary of analysed proteins and diseases
| Name | Symbol | PDB | OMIM | Disease(s) | Mutations |
| ABO blood group (transferase A, α1–3-N-acetylgalactosaminyltransferase; transferase B, α1–3-galactosyltransferase) | ABO | 1lzj | 110300 | Blood group variation | 22 |
| alanine-glyoxylate aminotransferase (oxalosis I; hyperoxaluria I; glycolicaciduria; serine-pyruvate aminotransferase) | AGXT | 1h0c | 604285 | Hyperoxaluria | 22 |
| arylsulfatase B | ARSB | 1fsu | 253200 | Mucopolysaccharidosis VI | 30 |
| argininosuccinate lyase | ASL | 1k62 | 608310 | Argininosuccinate lyase deficiency | 21 |
| Bruton agammaglobulinemia tyrosine kinase | BTK | 1btk, 1k2p | 300300 | X-linked agammaglobulinaemia | 144 |
| cystathionine-β-synthase | CBS | 1jbq | 236200 | Homocystinuria | 74 |
| CD40 ligand (TNF superfamily, member 5, hyper-IgM syndrome) | CD40LG | 1aly | 300386 | Hyper-IgM syndrome | 27 |
| cystic fibrosis transmembrane conductance regulator, ATP-binding cassette (sub-family C, member 7) | CFTR | 1xmj | 602421 | Asthma; Cystic fibrosis; Idiopathic pancreatitis; Congenital absence of vas deferens; Hereditary pancreatitis; Hypertrypsinaemia; Primary sclerosing cholangitis; Susceptibility to sarcoidosis; Idiopathic Bronchiectasis | 86 |
| CHK2 checkpoint homolog | CHEK2 | 1gxc | 604373 | Multiple cancers | 10 |
| doublecortex; lissencephaly, X-linked (doublecortin) | DCX | 1mjd | 300121 | Double cortex syndrome; X linked lissencephaly syndrome; Subcortical band heterotopia; Resistant partial seizures | 16 |
| cytochrome b5 reductase 3 | CYB5R3 | 1umk | 250800 | Methaemoglobinaemia | 18 |
| ectodysplasin A | EDA | 1rj7 | 300451 | Ectodermal dysplasia | 22 |
| coagulation factor XIII, A1 polypeptide | F13A1 | 1f13 | 134570 | Factor XIII deficiency | 30 |
| coagulation factor VIII, procoagulant component (hemophilia A) | F8 | 1iqd | 306700 | Haemophilia A | 39 |
| glucose-6-phosphate dehydrogenase | G6PD | 1qki | 305900 | Glucose-6-phosphate dehydrogenase deficiency | 130 |
| GTP cyclohydrolase 1 (dopa-responsive dystonia) | GCH1 | 1fb1 | 600225 | Dopa-responsive and progressive dystonia; Tetrahydrobiopterin deficiency | 45 |
| galactosidase, α | GLA | 1r46 | 301500 | Fabry disease | 179 |
| glucuronidase, β | GUSB | 1bhg | 253220 | Mucopolysaccharidosis VII; Hydrops fetalis | 28 |
| hemoglobin, β | HBB | 1o1p | 141900 | Haemoglobin variant; Haemolytic anaemia; β-thalassaemia; Erythrocytosis; Sickle cell anaemia | 160 |
| homogentisate 1,2-dioxygenase (homogentisate oxidase) | HGD | 1eyb | 607474 | Alkaptonuria | 29 |
| hypoxanthine phosphoribosyltransferase 1 (Lesch-Nyhan syndrome) | HPRT1 | 1bzy | 308000 | Hypoxanthine guanine phosphoribosyltransferase deficiency; Lesch-Nyhan syndrome; Hyperuricaemia; Hyperuricaemia with neurologic symptoms | 105 |
| insulin receptor | INSR | 1ir3 | 147670 | Leprechaunism; Insulin resistance; Insulin resistance A; Association with reduced diastolic blood pressure; Diabetes, NIDDM; Rabson-Mendenhall syndrome | 19 |
| lamin A/C | LMNA | 1ifr | 150330 | Muscular dystrophy; Emery-Dreifuss; Seip syndrome; Dilated cardiomyopathy; Partial lipodystrophy; Atypical Werner Syndrome; Familial autosomal dominant partial lipodystrophy (Dunnigan variety); Hutchinson-Gilford progeria syndrome; Charcot-Marie-Tooth disease 2; Cardiac conduction defects; Muscular dystrophy; Partial lipodystrophy; Mandibuloacral dysplasia; Association with metabolic syndrome | 22 |
| neurofibromin 2 (bilateral acoustic neuroma) | NF2 | 1h4r | 607379 | Neurofibromatosis 2 | 8 |
| ornithine aminotransferase (gyrate atrophy) | OAT | 2oat | 258870 | Gyrate atrophy | 27 |
| ornithine carbamoyltransferase | OTC | 1oth | 300461 | Ornithine transcarbamylase deficiency; Hyperammonaemia | 154 |
| phenylalanine hydroxylase | PAH | 1j8u | 261600 | Phenylketonuria; Hyperphenylalaninaemia | 240 |
| paired box gene 6 (aniridia, keratitis) | PAX6 | 6pax | 607108 | Aniridia; Congenital cataract; Peters' anomaly; Optic-nerve malformations; Congenital nystagmus; Ectopia pupillae; Isolated foveal hypoplasia; Ocular anterior segment anomaly | 27 |
| pyruvate dehydrogenase (lipoamide) α1 | PDHA1 | 1ni4 | 300502 | Pyruvate dehydrogenase deficiency; Lactic acidosis; Leigh syndrome | 40 |
| pyruvate kinase, liver and RBC | PKLR | 1liu | 266200 | Elevated red cell ATP; Haemolytic anaemia; Pyruvate kinase deficiency | 93 |
| prion protein (p27–30) (Creutzfeldt-Jakob disease, Gerstmann-Strausler-Scheinker syndrome, fatal familial insomnia) | PRNP | 1i4m | 176640 | Gerstmann-Straussler-Scheinker syndrome; Dementia; Creutzfeld-Jakob syndrome; Schizophrenia; Familial spongiform encephalopathy; Fatal familial insomnia; Prion disease | 23 |
| retinoblastoma 1 (including osteosarcoma) | RB1 | 1gux | 180200 | Retinoblastoma | 18 |
| solute carrier family 4, anion exchanger, member 1 (erythrocyte membrane protein band 3, Diego blood group) | SLC4A1 | 1hyn | 109270 | Spherocytosis; Blood group variation; Erythrocyte band 3 deficiency; Anaemia; Distal renal tubular acidosis; Acanthocytosis | 7 |
| superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) | SOD1 | 1mfm | 147450 | Amyotrophic lateral sclerosis; Motor neuron disease | 69 |
| sex determining region Y | SRY | 1j46 | 480000 | XY sex reversal; Gonadal dysgenesis; Hermaphroditism | 31 |
| transcription factor 1, hepatic; LF-B1, hepatic nuclear factor (HNF1), albumin proximal factor | TCF1 | 1ic8 | 142410 | Diabetes mellitus, type 2; MODY; MODY2; MODY3; Serum C-peptide and insulin response; Insulin resistance | 40 |
| thyroid hormone receptor, β thyroid hormone receptor, beta (erythroblastic leukemia viral (v-erb-a) oncogene homolog 2, avian) | THRB | 1nq2 | 190160 | Thyroid hormone resistance | 72 |
| troponin T type 2 (cardiac) | TNNT2 | 1j1d | 191045 | hypertrophic/dilated cardiomyopathy | 4 |
| troponin I type 3 (cardiac) | TNNI3 | 1j1e | 191044 | hypertrophic/restrictive cardiomyopathy | 7 |
| tumor protein p53 (Li-Fraumeni syndrome) | TP53 | 1tup | 191170 | Li-Fraumeni syndrome; Adrenocortical carcinoma; Sarcoma; Lung cancer; Breast cancer; Carcinoma; Glioma; Astrocytoma; Adrenocortical carcinoma; Glioblastoma; Cytosarcoma phyllodes; Osteosarcoma; Multiple cancers; Familial adenomatous polyposis; Rhabdomyosarcoma; Ependymoma; Adenocarcinoma; Thyroid tumour; Leukaemia/lymphoma; Neuroblastoma | 73 |
| uroporphyrinogen decarboxylase | UROD | 1r3s | 176100 | Porphyria cutanea tarda; Hepatoerythropoietic porphyria | 37 |
| uroporphyrinogen III synthase (congenital erythropoietic porphyria) | UROS | 1jr2 | 606938 | Erythropoietic porphyria; Guenther disease | 21 |
| vitamin D (1,25-dihydroxyvitamin D3) receptor | VDR | 1ie9, 1kb2 | 601769 | Higher bone mineral density; Rickets | 10 |
| von Hippel-Lindau tumor suppressor | VHL | 1lm8 | 608537 | von Hippel-Lindau syndrome; Phaeochromocytoma; Haemangioblastoma; Pancreatic cancer; Polycythemia, with high erythropoietin concentration; Phaeochromocytoma and paraganglioma | 134 |
Figure 1Amino acid distribution and relative mutability. Top row. Amino acid distribution in the investigated proteins (left), overall relative mutability of mutated (middle) and mutant residues (right). The same information is on the second row only for α-helices, third row for β-strands, fourth row for turns and bends, and in the bottom row for structures outside secondary structural elements.
Spectrum of mutations in all residues in the studied proteinsa
| Amino acid | Original residues | Expected residues | χ2 | Mutant residues | Expected residues | χ2 | ||
| A | 169 | 161 | 0.43 | 5.14E-01 | 83 | 148 | 1.05E-07 | |
| C | 79 | 38 | 4.51E-11 | 133 | 86 | 4.34E-07 | ||
| D | 98 | 131 | 4.00E-03 | 155 | 98 | 1.16E-08 | ||
| E | 113 | 168 | 2.43E-05 | 84 | 86 | 0.05 | 8.20E-01 | |
| F | 66 | 104 | 2.19E-04 | 90 | 98 | 0.72 | 3.97E-01 | |
| G | 246 | 167 | 1.02E-09 | 106 | 141 | 2.87E-03 | ||
| H | 87 | 61 | 1.05E-03 | 108 | 98 | 0.93 | 3.34E-01 | |
| I | 99 | 126 | 1.64E-02 | 80 | 129 | 1.52E-05 | ||
| K | 56 | 140 | 1.50E-12 | 109 | 86 | 1.36E-02 | ||
| L | 231 | 239 | 0.29 | 5.89E-01 | 113 | 203 | 2.70E-10 | |
| M | 78 | 58 | 8.15E-03 | 97 | 55 | 2.18E-08 | ||
| N | 90 | 92 | 0.03 | 8.58E-01 | 74 | 98 | 1.39E-02 | |
| P | 94 | 122 | 1.05E-02 | 194 | 148 | 1.35E-04 | ||
| Q | 62 | 102 | 8.24E-05 | 115 | 86 | 1.85E-03 | ||
| R | 348 | 142 | 4.48E-67 | 222 | 209 | 0.79 | 3.73E-01 | |
| S | 125 | 146 | 2.95 | 8.58E-02 | 174 | 228 | 3.84E-04 | |
| T | 84 | 123 | 4.08E-04 | 136 | 148 | 0.91 | 3.39E-01 | |
| V | 147 | 168 | 2.73 | 9.88E-02 | 185 | 148 | 2.09E-03 | |
| W | 55 | 37 | 2.24E-03 | 77 | 43 | 2.30E-07 | ||
| Y | 84 | 87 | 0.11 | 7.40E-01 | 76 | 74 | 0.07 | 7.98E-01 |
| Sum | 2411 | 2411 | 2411 | 2411 | ||||
aχ2-numbers in italics indicate underrepresentation and numbers in bold overrepresentation compared to random distribution based on amino acid frequencies. The results of the χ2 are shown with significance level: * P < 0.05; ** P < 0.01; *** P < 0.001.
Spectrum of mutations appearing in α-helix, β-strand, turn and bend structures, expected values are calculated from mutated and mutant amino acid composition in the studied proteinsa
| Amino acid | Original residues | Expected residues | χ2 | Mutant residues | Expected residues | χ2 | ||
| A | 148 | 136 | 1.07 | 3.00E-01 | 58 | 67 | 1.15 | 2.84E-01 |
| C | 54 | 64 | 1.43 | 2.32E-01 | 117 | 107 | 0.94 | 3.32E-01 |
| D | 81 | 79 | 0.06 | 8.06E-01 | 112 | 125 | 1.28 | 2.57E-01 |
| E | 96 | 91 | 0.29 | 5.91E-01 | 71 | 68 | 0.18 | 6.75E-01 |
| F | 53 | 53 | 0.00 | 9.91E-01 | 77 | 72 | 0.29 | 5.87E-01 |
| G | 220 | 198 | 2.48 | 1.15E-01 | 95 | 85 | 1.12 | 2.91E-01 |
| H | 63 | 70 | 0.69 | 4.05E-01 | 91 | 87 | 0.20 | 6.57E-01 |
| I | 83 | 80 | 0.14 | 7.05E-01 | 55 | 64 | 1.36 | 2.44E-01 |
| K | 43 | 45 | 0.09 | 7.61E-01 | 92 | 88 | 0.21 | 6.43E-01 |
| L | 188 | 186 | 0.03 | 8.70E-01 | 96 | 91 | 0.29 | 5.91E-01 |
| M | 65 | 63 | 0.08 | 7.74E-01 | 48 | 78 | 6.79E-04 | |
| N | 60 | 72 | 2.12 | 1.46E-01 | 61 | 60 | 0.04 | 8.47E-01 |
| P | 68 | 76 | 0.76 | 3.82E-01 | 170 | 156 | 1.25 | 2.63E-01 |
| Q | 45 | 50 | 0.47 | 4.91E-01 | 89 | 92 | 0.13 | 7.17E-01 |
| R | 299 | 280 | 1.31 | 2.53E-01 | 196 | 179 | 1.71 | 1.91E-01 |
| S | 78 | 101 | 2.46E-02 | 144 | 140 | 0.12 | 7.31E-01 | |
| T | 62 | 68 | 0.46 | 4.99E-01 | 119 | 109 | 0.85 | 3.57E-01 |
| V | 122 | 118 | 0.12 | 7.28E-01 | 138 | 149 | 0.78 | 3.77E-01 |
| W | 44 | 44 | 0.00 | 9.72E-01 | 56 | 62 | 0.57 | 4.51E-01 |
| Y | 67 | 68 | 0.00 | 9.46E-01 | 54 | 61 | 0.83 | 3.62E-01 |
| Sum | 1939 | 1939 | 1939 | 1939 | ||||
aχ2-numbers in italics indicate underrepresentation and numbers in bold overrepresentation compared to random distribution based on amino acid frequencies. The results of the χ2 are shown with significance level: * P < 0.05; ** P < 0.01; *** P < 0.001.
Spectrum of mutations appearing in α-helix, β-strand, turn and bend structures. Expected values are calculated from amino acid composition in secondary structural elementsa
| Amino acid | Original residues | Expected residues | χ2 | Mutant residues | Expected residues | χ2 | ||
| A | 148 | 139 | 0,53 | 4.66E-01 | 58 | 119 | 2.51E-08 | |
| C | 54 | 32 | 6.82E-05 | 117 | 69 | 9.58E-09 | ||
| D | 81 | 96 | 2,34 | 1.26E-01 | 112 | 79 | 2.21E-04 | |
| E | 96 | 147 | 2.71E-05 | 71 | 69 | 0.04 | 8.33E-01 | |
| F | 53 | 87 | 2.36E-04 | 77 | 79 | 0.06 | 8.10E-01 | |
| G | 220 | 136 | 4.48E-13 | 95 | 114 | 3.10 | 7.85E-02 | |
| H | 63 | 48 | 2.47E-02 | 91 | 79 | 1.78 | 1.83E-01 | |
| I | 83 | 110 | 1.07E-02 | 55 | 104 | 1.62E-06 | ||
| K | 43 | 113 | 4.37E-11 | 92 | 69 | 6.26E-03 | ||
| L | 188 | 205 | 1,34 | 2.46E-01 | 96 | 163 | 1.42E-07 | |
| M | 65 | 49 | 2.51E-02 | 48 | 45 | 0.27 | 6.02E-01 | |
| N | 60 | 69 | 1,10 | 2.93E-01 | 61 | 79 | 4.14E-02 | |
| P | 68 | 67 | 0,02 | 8.98E-01 | 170 | 119 | 2.51E-06 | |
| Q | 45 | 82 | 3.98E-05 | 89 | 69 | 1.76E-02 | ||
| R | 299 | 119 | 3.43E-61 | 196 | 168 | 3.19E-02 | ||
| S | 78 | 104 | 1.01E-02 | 144 | 183 | 3.92E-03 | ||
| T | 62 | 92 | 1.53E-03 | 119 | 119 | 0.00 | 9.79E-01 | |
| V | 122 | 144 | 3,33 | 7.01E-02 | 138 | 119 | 3.13 | 7.67E-02 |
| W | 44 | 30 | 1.23E-02 | 56 | 35 | 2.81E-04 | ||
| Y | 67 | 70 | 0,15 | 6.95E-01 | 54 | 59 | 0.48 | 4.87E-01 |
| Sum | 1939 | 1939 | 1939 | 1939 | ||||
aχ2-numbers in italics indicate underrepresentation and numbers in bold overrepresentation compared to random distribution based on amino acid frequencies. The results of the χ2 are shown with significance level: * P < 0.05; ** P < 0.01; *** P < 0.001.
Spectrum of mutations in α-helicesa
| Amino acid | Original residues | Expected residues | χ2 | Mutant residues | Expected residues | χ2 | ||
| A | 89 | 83 | 0.45 | 5.03E-01 | 23 | 57 | 7.25E-06 | |
| C | 26 | 14 | 7.88E-04 | 56 | 33 | 7.18E-05 | ||
| D | 34 | 44 | 2.23 | 1.35E-01 | 59 | 38 | 5.99E-04 | |
| E | 61 | 96 | 3.64E-04 | 26 | 33 | 1.54 | 2.15E-01 | |
| F | 28 | 36 | 1.76 | 1.84E-01 | 37 | 38 | 0.02 | 8.87E-01 |
| G | 48 | 30 | 1.08E-03 | 46 | 54 | 1.31 | 2.52E-01 | |
| H | 23 | 21 | 0.13 | 7.19E-01 | 41 | 38 | 0.26 | 6.12E-01 |
| I | 41 | 51 | 1.96 | 1.61E-01 | 29 | 50 | 3.30E-03 | |
| K | 20 | 61 | 1.41E-07 | 52 | 33 | 1.05E-03 | ||
| L | 101 | 112 | 1.04 | 3.09E-01 | 49 | 78 | 9.85E-04 | |
| M | 41 | 29 | 2.37E-02 | 24 | 21 | 0.34 | 5.59E-01 | |
| N | 22 | 27 | 1.08 | 3.00E-01 | 29 | 38 | 2.08 | 1.49E-01 |
| P | 29 | 24 | 1.15 | 2.84E-01 | 90 | 57 | 1.07E-05 | |
| Q | 28 | 45 | 1.34E-02 | 55 | 33 | 1.47E-04 | ||
| R | 153 | 64 | 1.56E-28 | 73 | 80 | 0.70 | 4.04E-01 | |
| S | 36 | 46 | 2.22 | 1.36E-01 | 53 | 88 | 2.19E-04 | |
| T | 30 | 38 | 1.84 | 1.75E-01 | 61 | 57 | 0.31 | 5.79E-01 |
| V | 62 | 59 | 0.18 | 6.69E-01 | 69 | 57 | 2.61 | 1.06E-01 |
| W | 24 | 16 | 4.06E-02 | 32 | 17 | 1.51E-04 | ||
| Y | 32 | 33 | 0.01 | 9.29E-01 | 24 | 28 | 0.68 | 4.08E-01 |
| Sum | 928 | 928 | 928 | 928 | ||||
aχ2-numbers in italics indicate underrepresentation and numbers in bold overrepresentation compared to random distribution based on amino acid frequencies. The results of the χ2 are shown with significance level: * P < 0.05; ** P < 0.01; *** P < 0.001.
Spectrum of mutations in β-strandsa
| Amino acid | Original residues | Expected residues | χ2 | Mutant residues | Expected residues | χ2 | ||
| A | 39 | 33 | 0.93 | 3.34E-01 | 14 | 34 | 6.98E-04 | |
| C | 19 | 12 | 3.24E-02 | 39 | 20 | 1.26E-05 | ||
| D | 17 | 15 | 0.22 | 6.38E-01 | 26 | 22 | 0.56 | 4.54E-01 |
| E | 21 | 25 | 0.64 | 4.23E-01 | 20 | 20 | 0.01 | 9.36E-01 |
| F | 15 | 36 | 3.75E-04 | 24 | 22 | 0.11 | 7.43E-01 | |
| G | 44 | 27 | 1.13E-03 | 27 | 32 | 0.86 | 3.54E-01 | |
| H | 23 | 13 | 3.90E-03 | 32 | 22 | 4.38E-02 | ||
| I | 34 | 49 | 2.84E-02 | 16 | 29 | 1.31E-02 | ||
| K | 13 | 23 | 3.20E-02 | 23 | 20 | 0.57 | 4.49E-01 | |
| L | 63 | 66 | 0.10 | 7.48E-01 | 27 | 46 | 4.56E-03 | |
| M | 14 | 13 | 0.03 | 8.53E-01 | 16 | 13 | 0.90 | 3.43E-01 |
| N | 19 | 14 | 1.67 | 1.97E-01 | 20 | 22 | 0.27 | 6.05E-01 |
| P | 15 | 11 | 1.08 | 2.99E-01 | 47 | 34 | 2.16E-02 | |
| Q | 10 | 16 | 2.24 | 1.34E-01 | 20 | 20 | 0.01 | 9.36E-01 |
| R | 77 | 29 | 3.69E-19 | 60 | 48 | 3.17 | 7.50E-02 | |
| S | 15 | 23 | 2.88 | 8.98E-02 | 55 | 52 | 0.18 | 6.68E-01 |
| T | 16 | 35 | 1.41E-03 | 36 | 34 | 0.16 | 6.88E-01 | |
| V | 53 | 71 | 3.51E-02 | 27 | 34 | 1.32 | 2.50E-01 | |
| W | 16 | 10 | 3.23 | 7.25E-02 | 8 | 10 | 0.34 | 5.61E-01 |
| Y | 27 | 27 | 0.00 | 9.60E-01 | 13 | 17 | 0.87 | 3.50E-01 |
| Sum | 550 | 550 | 550 | 550 | ||||
aχ2-numbers in italics indicate underrepresentation and numbers in bold overrepresentation compared to random distribution based on amino acid frequencies. The results of the χ2 are shown with significance level: * P < 0.05; ** P < 0.01; *** P < 0.001.
Spectrum of mutations in turns and bendsa
| Amino acid | Original residues | Expected residues | χ2 | Mutant residues | Expected residues | χ2 | ||
| A | 20 | 24 | 0.79 | 3.73E-01 | 21 | 28 | 1.85 | 1.74E-01 |
| C | 9 | 7 | 0.97 | 3.26E-01 | 22 | 16 | 1.86 | 1.72E-01 |
| D | 30 | 35 | 0.70 | 4.04E-01 | 27 | 19 | 3.56 | 5.92E-02 |
| E | 14 | 27 | 1.22E-02 | 25 | 16 | 3.54E-02 | ||
| F | 10 | 16 | 2.13 | 1.45E-01 | 16 | 19 | 0.42 | 5.16E-01 |
| G | 128 | 72 | 4.87E-11 | 22 | 27 | 0.94 | 3.32E-01 | |
| H | 17 | 13 | 1.12 | 2.91E-01 | 18 | 19 | 0.04 | 8.51E-01 |
| I | 8 | 12 | 1.20 | 2.73E-01 | 10 | 25 | 3.10E-03 | |
| K | 10 | 28 | 5.92E-04 | 17 | 16 | 0.02 | 8.95E-01 | |
| L | 24 | 30 | 1.27 | 2.60E-01 | 20 | 39 | 2.53E-03 | |
| M | 10 | 8 | 0.67 | 4.13E-01 | 8 | 11 | 0.63 | 4.27E-01 |
| N | 19 | 26 | 1.72 | 1.90E-01 | 12 | 19 | 2.47 | 1.16E-01 |
| P | 24 | 29 | 1.02 | 3.12E-01 | 33 | 28 | 0.81 | 3.69E-01 |
| Q | 7 | 21 | 1.84E-03 | 14 | 16 | 0.37 | 5.44E-01 | |
| R | 69 | 26 | 5.44E-17 | 63 | 40 | 2.73E-04 | ||
| S | 27 | 34 | 1.27 | 2.59E-01 | 36 | 44 | 1.30 | 2.55E-01 |
| T | 16 | 20 | 0.68 | 4.09E-01 | 22 | 28 | 1.37 | 2.41E-01 |
| V | 7 | 17 | 1.39E-02 | 42 | 28 | 9.52E-03 | ||
| W | 4 | 5 | 0.07 | 7.92E-01 | 16 | 8 | 6.78E-03 | |
| Y | 8 | 11 | 1.02 | 3.13E-01 | 17 | 14 | 0.59 | 4.42E-01 |
| Sum | 461 | 461 | 461 | 461 | ||||
aχ2-numbers in italics indicate underrepresentation and numbers in bold overrepresentation compared to random distribution based on amino acid frequencies. The results of the χ2 are shown with significance level: * P < 0.05; ** P < 0.01; *** P < 0.001.
Mutated and mutant residues not in secondary structuresa
| Amino acid group | Original residues | Expected residues | χ2 | P value | Mutant residues | Expected residues | χ2 | P value |
| A | 18 | 22 | 0.84 | 3.58E-01 | 21 | 29 | 2.16 | 1.42E-01 |
| C | 12 | 7 | 4.51 | 3.37E-02 | 25 | 17 | 4.73E-02 | |
| D | 46 | 34 | 4.20 | 4.04E-02 | 17 | 19 | 0.27 | 6.06E-01 |
| E | 10 | 22 | 1.06E-02 | 17 | 17 | 0.00 | 9.72E-01 | |
| F | 15 | 17 | 0.17 | 6.83E-01 | 13 | 19 | 2.04 | 1.53E-01 |
| G | 35 | 32 | 0.37 | 5.40E-01 | 26 | 28 | 0.10 | 7.48E-01 |
| H | 27 | 14 | 3.04E-04 | 24 | 19 | 1.16 | 2.81E-01 | |
| I | 19 | 17 | 0.23 | 6.32E-01 | 16 | 25 | 3.41 | 6.48E-02 |
| K | 11 | 27 | 2.49E-03 | 13 | 17 | 0.88 | 3.47E-01 | |
| L | 29 | 36 | 1.36 | 2.44E-01 | 43 | 40 | 0.27 | 6.04E-01 |
| M | 6 | 9 | 0.93 | 3.36E-01 | 13 | 11 | 0.43 | 5.11E-01 |
| N | 10 | 23 | 8.34E-03 | 30 | 19 | 1.45E-02 | ||
| P | 61 | 52 | 1.44 | 2.29E-01 | 26 | 29 | 0.29 | 5.90E-01 |
| Q | 3 | 20 | 1.86E-04 | 17 | 17 | 0.00 | 9.72E-01 | |
| R | 53 | 23 | 9.51E-10 | 49 | 41 | 1.59 | 2.08E-01 | |
| S | 31 | 40 | 2.13 | 1.45E-01 | 47 | 45 | 0.13 | 7.14E-01 |
| T | 24 | 30 | 1.25 | 2.63E-01 | 22 | 29 | 1.65 | 1.99E-01 |
| V | 25 | 25 | 0.00 | 9.44E-01 | 25 | 29 | 0.53 | 4.68E-01 |
| W | 8 | 6 | 0.41 | 5.22E-01 | 11 | 8 | 0.78 | 3.76E-01 |
| Y | 29 | 17 | 3.06E-03 | 17 | 14 | 0.45 | 5.02E-01 | |
| Sum | 472 | 472 | 472 | 472 | ||||
aχ2-numbers in italics indicate underrepresentation and numbers in bold overrepresentation compared to random distribution based on amino acid frequencies. The results of the χ2 are shown with significance level: * P < 0.05; ** P < 0.01; *** P < 0.001.
Spectrum of mutations in α-helices in amino acid groupsa
| Amino acid group | Original residues | Expected residues | χ2 | Mutant residues | Expected residues | χ2 | ||
| Hydrophobic | 355 | 348 | 0.13 | 7.19E-01 | 320 | 322 | 0.01 | 9.13E-01 |
| Positively charged | 95 | 140 | 1.51E-04 | 85 | 71 | 2.75 | 9.71E-02 | |
| Negatively charged | 196 | 147 | 4.71E-05 | 166 | 152 | 1.39 | 2.39E-01 | |
| Conformational | 77 | 54 | 1.60E-03 | 136 | 111 | 1.90E-02 | ||
| Polar | 86 | 118 | 3.17E-03 | 137 | 159 | 2.94 | 8.62E-02 | |
| A+T | 119 | 121 | 0.04 | 8.34E-01 | 84 | 114 | 5.44E-03 | |
| Sum | 928 | 928 | 928 | 928 | ||||
aχ2-numbers in italics indicate underrepresentation and numbers in bold overrepresentation compared to random distribution based on amino acid frequencies. The results of the χ2 are shown with significance level: * P < 0.05; ** P < 0.01; *** P < 0.001.
Spectrum of mutations in β-strands in amino acid groupsa
| Amino acid group | Original residues | Expected residues | χ2 | Mutant residues | Expected residues | χ2 | ||
| Hydrophobic | 241 | 285 | 9.54E-03 | 170 | 191 | 2.27 | 1.32E-01 | |
| Positively charged | 38 | 40 | 0.12 | 7.31E-01 | 46 | 42 | 0.36 | 5.47E-01 |
| Negatively charged | 113 | 65 | 2.58E-09 | 115 | 90 | 7.82E-03 | ||
| Conformational | 59 | 39 | 9.81E-04 | 74 | 66 | 0.98 | 3.21E-01 | |
| Polar | 44 | 53 | 1.62 | 2.03E-01 | 95 | 94 | 0.01 | 9.18E-01 |
| A+T | 55 | 68 | 2.58 | 1.08E-01 | 50 | 67 | 3.45E-02 | |
| Sum | 550 | 550 | 550 | 550 | ||||
aχ2-numbers in italics indicate underrepresentation and numbers in bold overrepresentation compared to random distribution based on amino acid frequencies. The results of the χ2 are shown with significance level: * P < 0.05; ** P < 0.01; *** P < 0.001.
Spectrum of mutations in turns and bends in amino acid groupsa
| Amino acid group | Original residues | Expected residues | χ2 | Mutant residues | Expected residues | χ2 | ||
| Hydrophobic | 80 | 105 | 1.42E-02 | 151 | 160 | 0.50 | 4.80E-01 | |
| Positively charged | 44 | 62 | 2.24E-02 | 52 | 35 | 4.88E-03 | ||
| Negatively charged | 96 | 68 | 5.48E-04 | 98 | 75 | 8.78E-03 | ||
| Conformational | 152 | 102 | 5.90E-07 | 55 | 55 | 0.00 | 9.71E-01 | |
| Polar | 53 | 81 | 2.12E-03 | 62 | 79 | 3.58 | 5.85E-02 | |
| A+T | 36 | 44 | 1.48 | 2.24E-01 | 43 | 56 | 3.20 | 7.34E-02 |
| Sum | 461 | 461 | 461 | 461 | ||||
aχ2-numbers in italics indicate underrepresentation and numbers in bold overrepresentation compared to random distribution based on amino acid frequencies. The results of the χ2 are shown with significance level: * P < 0.05; ** P < 0.01; *** P < 0.001.
Figure 2Changes to properties of amino acids caused by mutations. Average changes per residue in residue volumes when comparing original amino acid and mutated amino acid in A) α-helices, β-strands, turns and bends and B) separately in α-helices (H), 310-helices (G), extended strands (E), isolated β-bridges (B), turns (T) and bends (S). C) Average changes per residue in charges when comparing original amino acid and mutated amino acid in α-helices, β-strands, turns and bends and D) separately in α-helices, 310-helices, extended strands, isolated β-bridges, turns and bends.
Figure 3Changes in mutations to residue volumes. Average changes in mutations to residue volumes in α-helices (red), β-strands (blue), turns and bends (green). The thick line indicates the original amino acid volumes. Outer rings indicate addition in volume and inner rings reduction, in steps of 35 Å3.
Figure 4Changes in mutations to residue charges. Average changes in mutations to residue charges in α-helices (red), β-strands (blue), turns and bends (green). The thick line indicates the original amino acid charges. Outer rings indicate higher charge values and inner rings lower, in steps of 1.25 pI.
Figure 5Distribution of contact energies for mutated amino acids. The energies were calculated with the RankViaContact program. A) Data for all mutations, and B) distribution in secondary structural elements α-helices (red), β-strands (blue), turns and bends (green), outside secondary structures (yellow), and whole proteins (black).
Figure 6Mutant residues with strong and weak contact energies. The percentage of mutant residues with strong (black) and weak (white) contact energies in physicochemical amino acid groups.